세계의 유전자 클로닝 서비스 시장 : 시장 규모 및 점유율 분석 - 서비스별, 용도별, 유전자 유형별, 최종사용자별 - 산업 수요 예측(-2030년)
Gene Cloning Services Market Size and Share Analysis by Service, Application, Gene Type, End User - Global Industry Demand Forecast to 2030
시장 개요
세계의 유전자 클로닝 서비스 시장 규모는 2023년에 31억 5,410만 달러로 추계되며, 2024-2030년 18.1%의 CAGR로 성장하며, 2030년에는 100억 1,960만 달러에 달할 것으로 예측되고 있습니다.
만성질환의 증가, 정확한 의약품에 대한 요구의 증가, 유전성 질환의 대폭적인 발생이 업계의 발전에 기여할 것으로 예측됩니다. 또한 정부에 의한 지출의 증가, 바이오테크놀러지 분야의 연구개발, 유전학 기술 향상에 의해 의약품 분야의 연구가 대폭 급증하며, 향후 수년간 업계의 매출을 촉진할 것으로 예측됩니다.
주요 인사이트
2023년, 유전자 합성 카테고리는 45%의 업계 점유율을 차지하고 있습니다. 보급은 다수의 수직 분야에서의 광범위한 응용과 세계 연구 활동의 성장에 기인합니다.
2023년, 유전자 치료는 업계 점유율의 35%를 차지하고 있습니다. 성장 가능성은 이전에는 구제할 수 없었던 질병 및 질환을 치료하는 능력에 있습니다.
2023년 현재, 북미 지역이 약 55%의 업계 최대 점유율을 차지하고 있으며, 이것은 바이오테크놀러지 및 제약 산업에서 연구개발이 번성하기 때문입니다.
세계의 유전자 클로닝 서비스 시장을 분석했으며, 시장의 기본 구조·최신 상황 및 주요 촉진·억제요인, 세계 전체 및 지역별·주요 국가 시장 규모의 동향 전망(금액 기반, 2017-2030년), 서비스별·용도별·유전자 유형별·최종사용자별의 상세 동향, 현재의 시장 경쟁 상황, 주요 기업의 개요 등을 조사하여 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계의 전망
- 시장 역학
- 동향
- 촉진요인
- 억제요인/과제
- 촉진요인/억제요인의 영향 분석
- 신종 코로나바이러스 감염증(COVID-19)의 영향
- Porter's Five Forces 분석
제6장 세계 시장
- 개요
- 시장 매출 : 서비스별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 유전자 유형별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 서비스별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 유전자 유형별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카 시장
제12장 미국 시장
- 개요
- 시장 매출 : 서비스별(2017-2030년)
- 시장 매출 : 용도별(2017-2030년)
- 시장 매출 : 유전자 유형별(2017-2030년)
- 시장 매출 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카공화국 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 참여 기업과 제공 제품/서비스 리스트
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근 전략 개발 상황
제30장 기업 개요
- Thermo Fisher Scientific Inc.
- Genscript Biotech Corporation
- Eurofins Scientific SE
- Charles River Laboratories International Inc.
- Takara Bio Inc.
- Creative Biogene
- Synbio Technologies
- Aragen Life Sciences Ltd.
- Sino Biological Inc.
- Curia Global Inc.
제31장 부록
KSA
Market Overview
The market value of global gene cloning services is estimated to be USD 3,154.1 million in 2023 and is projected to reach USD 10,019.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 18.1% during the period from 2024 to 2030.
The rising occurrence of chronic illnesses, the growing need for accurate drugs, and the substantial occurrence of inherited conditions are projected to contribute to the development of the industry. Moreover, the substantial surge in research in the medicinal field because of the rise in spending by governments, the development of the biotechnological sector, and technical improvements in genetics are projected to propel the industry revenue in the coming years.
Nowadays we see a growing trend of a sedentary way of life, which goes with alcohol consumption, increased smoking, terminal fast food, and exercise too rare. The adoption of this unhealthy diet is causing the state of health of people to be even more unhealthy and also the development of many long-term diseases.
Diseases make things worse and serious diseases will be the things that can even end the life of a person. This therefore led to an increase in the need for such methods of treatments that are either more efficient or more effective in curing the disease.
Key Insights
In 2023, the gene synthesis category grips the dominating industry share of 45%.
Its acceptance stems from its extensive application in numerous verticals and the growing research activities globally.
Researchers are progressively using gene synthesis along with techs such as CRISPR genome editing and synthetic biology for enhanced solutions in life sciences.
Gene synthesis can be used in the fields of neurosciences, therapeutic antibody structure development, plant biology, cancer biology, genetics, and biochemistry.
Initially, it is considered a tool pushed to the front for economical tasks of the traditional cloning and molecular biology method that sometimes need time and are expensive.
In 2023, gene therapy grips a leading industry share of 35%.
Its potential lies in its capability to cure previously irredeemable ailments or diseases.
More than 50,000 inherited illnesses caused by gene mutations have been recognized, making gene treatment a promising method.
Understanding protein pathways and gene expression allows for the testing and effectiveness of more therapies.
In 2023, the North American region holds the largest industry share of approximately 55% because of substantial R&D in the biotechnology and pharmaceutical industries.
Reasons contributing to this comprise the high occurrence of chronic illnesses, a strong healthcare system, and acceptance of enhanced technologies.
Top biotechnology businesses and genomic research projects with significant investments are propelling industry development.
Positive perceptions of health and genetic testing to individuals may stimulate research of genomics in medicine to evaluate therapeutic purposes.
Due to the well-established healthcare, general public knowledge, and individual capacity of a modern person to cover the expenses related to treatment, and along with the implementation of gene therapies for cancer, Canada provides the largest market share in North America.
Enhanced healthcare coverage as well as steady improvement of pharmaceutical and biotech industries is going to result in a substantial portion in the forecast. Additionally, rising chronic diseases, and growing gene cloning in diagnostic and drug development, will support Europe in ranking within the top five markets.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by service
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by gene type
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Service (2017-2030)
- 6.3. Market Revenue, by Application (2017-2030)
- 6.4. Market Revenue, by Gene Type (2017-2030)
- 6.5. Market Revenue, by End User (2017-2030)
- 6.6. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Service (2017-2030)
- 7.3. Market Revenue, by Application (2017-2030)
- 7.4. Market Revenue, by Gene Type (2017-2030)
- 7.5. Market Revenue, by End User (2017-2030)
- 7.6. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Service (2017-2030)
- 8.3. Market Revenue, by Application (2017-2030)
- 8.4. Market Revenue, by Gene Type (2017-2030)
- 8.5. Market Revenue, by End User (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Service (2017-2030)
- 9.3. Market Revenue, by Application (2017-2030)
- 9.4. Market Revenue, by Gene Type (2017-2030)
- 9.5. Market Revenue, by End User (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Service (2017-2030)
- 10.3. Market Revenue, by Application (2017-2030)
- 10.4. Market Revenue, by Gene Type (2017-2030)
- 10.5. Market Revenue, by End User (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Service (2017-2030)
- 11.3. Market Revenue, by Application (2017-2030)
- 11.4. Market Revenue, by Gene Type (2017-2030)
- 11.5. Market Revenue, by End User (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Service (2017-2030)
- 12.3. Market Revenue, by Application (2017-2030)
- 12.4. Market Revenue, by Gene Type (2017-2030)
- 12.5. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Service (2017-2030)
- 13.3. Market Revenue, by Application (2017-2030)
- 13.4. Market Revenue, by Gene Type (2017-2030)
- 13.5. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Service (2017-2030)
- 14.3. Market Revenue, by Application (2017-2030)
- 14.4. Market Revenue, by Gene Type (2017-2030)
- 14.5. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Service (2017-2030)
- 15.3. Market Revenue, by Application (2017-2030)
- 15.4. Market Revenue, by Gene Type (2017-2030)
- 15.5. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Service (2017-2030)
- 16.3. Market Revenue, by Application (2017-2030)
- 16.4. Market Revenue, by Gene Type (2017-2030)
- 16.5. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Service (2017-2030)
- 17.3. Market Revenue, by Application (2017-2030)
- 17.4. Market Revenue, by Gene Type (2017-2030)
- 17.5. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Service (2017-2030)
- 18.3. Market Revenue, by Application (2017-2030)
- 18.4. Market Revenue, by Gene Type (2017-2030)
- 18.5. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Service (2017-2030)
- 19.3. Market Revenue, by Application (2017-2030)
- 19.4. Market Revenue, by Gene Type (2017-2030)
- 19.5. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Service (2017-2030)
- 20.3. Market Revenue, by Application (2017-2030)
- 20.4. Market Revenue, by Gene Type (2017-2030)
- 20.5. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Service (2017-2030)
- 21.3. Market Revenue, by Application (2017-2030)
- 21.4. Market Revenue, by Gene Type (2017-2030)
- 21.5. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Service (2017-2030)
- 22.3. Market Revenue, by Application (2017-2030)
- 22.4. Market Revenue, by Gene Type (2017-2030)
- 22.5. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Service (2017-2030)
- 23.3. Market Revenue, by Application (2017-2030)
- 23.4. Market Revenue, by Gene Type (2017-2030)
- 23.5. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Service (2017-2030)
- 24.3. Market Revenue, by Application (2017-2030)
- 24.4. Market Revenue, by Gene Type (2017-2030)
- 24.5. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Service (2017-2030)
- 25.3. Market Revenue, by Application (2017-2030)
- 25.4. Market Revenue, by Gene Type (2017-2030)
- 25.5. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Service (2017-2030)
- 26.3. Market Revenue, by Application (2017-2030)
- 26.4. Market Revenue, by Gene Type (2017-2030)
- 26.5. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Service (2017-2030)
- 27.3. Market Revenue, by Application (2017-2030)
- 27.4. Market Revenue, by Gene Type (2017-2030)
- 27.5. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Service (2017-2030)
- 28.3. Market Revenue, by Application (2017-2030)
- 28.4. Market Revenue, by Gene Type (2017-2030)
- 28.5. Market Revenue, by End User (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Thermo Fisher Scientific Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. Genscript Biotech Corporation
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Eurofins Scientific SE
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Charles River Laboratories International Inc.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Takara Bio Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Creative Biogene
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Synbio Technologies
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Aragen Life Sciences Ltd.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Sino Biological Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Curia Global Inc.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
